U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H27NO9
Molecular Weight 461.4618
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MORPHINE-3-GLUCURONIDE

SMILES

[H][C@]12C=C[C@H](O)[C@@H]3OC4=C5C(C[C@H]1N(C)CC[C@@]235)=CC=C4O[C@@H]6O[C@@H]([C@@H](O)[C@H](O)[C@H]6O)C(O)=O

InChI

InChIKey=WAEXKFONHRHFBZ-ZXDZBKESSA-N
InChI=1S/C23H27NO9/c1-24-7-6-23-10-3-4-12(25)20(23)32-18-13(5-2-9(14(18)23)8-11(10)24)31-22-17(28)15(26)16(27)19(33-22)21(29)30/h2-5,10-12,15-17,19-20,22,25-28H,6-8H2,1H3,(H,29,30)/t10-,11+,12-,15-,16-,17+,19-,20-,22+,23-/m0/s1

HIDE SMILES / InChI

Molecular Formula C23H27NO9
Molecular Weight 461.4618
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

PubMed

PubMed

TitleDatePubMed
Lack of effect of ondansetron on the pharmacokinetics and analgesic effects of morphine and metabolites after single-dose morphine administration in healthy volunteers.
2001 Apr
Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries.
2001 Dec
Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide.
2001 Jun 15
Limited phase I study of morphine-3-glucuronide.
2001 Nov
Discriminative stimulus effects of intravenous heroin and its metabolites in rhesus monkeys: opioid and dopaminergic mechanisms.
2001 Nov
Ethnicity influences morphine pharmacokinetics and pharmacodynamics.
2001 Oct
The role of the hydrophilic Asn230 residue of the mu-opioid receptor in the potency of various opioid agonists.
2001 Oct
LC determination of morphine and morphine glucuronides in human plasma by coulometric and UV detection.
2001 Sep
Quantitative gas chromatographic/mass spectrometric analysis of morphine glucuronides in human plasma by negative ion chemical ionization mass spectrometry.
2002 Apr
Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.
2002 Dec
Pharmacokinetic evaluation of a sprinkle-dose regimen of a once-daily, extended-release morphine formulation.
2002 Feb
Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.
2002 Feb
Diclofenac does not interact with codeine metabolism in vivo: a study in healthy volunteers.
2002 Feb 27
Sex-specific differences in levels of morphine, morphine-3-glucuronide, and morphine antinociception in rats.
2002 Jan
The study of codeine-gluthetimide pharmacokinetic interaction in rats.
2003 Aug 8
Influences on serum concentrations of morphine, M6G and M3G during routine clinical drug monitoring: a prospective survey in 300 adult cancer patients.
2003 Jul
A novel metabolic pathway of morphine: formation of morphine glucosides in cancer patients.
2003 Jun
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
2003 Jun
Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain.
2003 Mar
Production of a recombinant anti-morphine-3-glucuronide single-chain variable fragment (scFv) antibody for the development of a "real-time" biosensor-based immunoassay.
2003 May 1
Repeated exposures to heroin and/or cadmium alter the rate of formation of morphine glucuronides in the rat.
2003 Nov
High levels of morphine-6-glucuronide in street heroin addicts.
2003 Nov
Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts.
2003 Oct
Interpretation of the presence of 6-monoacetylmorphine in the absence of morphine-3-glucuronide in urine samples: evidence of heroin abuse.
2003 Oct
Bioavailability of a morphine suppository is increased after intracolostomal administration in colostoma-constructed rabbits.
2003 Oct 20
Determination of morphine and morphine glucuronides in human plasma by 96-well plate solid-phase extraction and liquid chromatography-electrospray ionization mass spectrometry.
2003 Oct 25
Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7.
2003 Sep
Development and validation of a liquid chromatography-mass spectrometry assay for the determination of opiates and cocaine in meconium.
2003 Sep 5
Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.
2004 Jun
The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease.
2004 Nov
Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study.
2004 Oct 4
On-line desalting and determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in microdialysis and plasma samples using column switching and liquid chromatography/tandem mass spectrometry.
2005
Is morphine-3-glucuronide of therapeutic relevance?
2005 Aug
Effects of morphine and its metabolites on immune function in advanced cancer patients.
2005 Dec
Novel assay format permitting the prolonged use of regeneration-based sensor chip technology.
2005 Jan
The contribution of fetal metabolism to the disposition of morphine.
2005 Jan
Age-dependent morphine tolerance development in the rat.
2005 Jun
HPLC with laser-induced native fluorescence detection for morphine and morphine glucuronides from blood after immunoaffinity extraction.
2005 May
LC-ESI-MS/MS analysis for the quantification of morphine, codeine, morphine-3-beta-D-glucuronide, morphine-6-beta-D-glucuronide, and codeine-6-beta-D-glucuronide in human urine.
2005 Nov
Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4.
2005 Oct
Effect of repeated administrations of heroin, naltrexone, methadone, and alcohol on morphine glucuronidation in the rat.
2005 Oct
Mechanisms of nociception evoked by intrathecal high-dose morphine.
2005 Oct
Development and validation of a radioreceptor assay for the determination of morphine and its active metabolites in serum.
2005 Oct 4
Fetal morphine metabolism and clearance are constant during late gestation.
2006 Apr
Optimizing recombinant antibody function in SPR immunosensing. The influence of antibody structural format and chip surface chemistry on assay sensitivity.
2006 Aug 15
Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: evidence for multiple diverse hyperalgesic systems.
2006 Jan 27
Direct nose-to-brain transfer of morphine after nasal administration to rats.
2006 Mar
Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.
2006 Mar
An automated and fully validated LC-MS/MS procedure for the simultaneous determination of 11 opioids used in palliative care, with 5 of their metabolites.
2006 May
Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation.
2006 May
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:24:09 GMT 2023
Edited
by admin
on Fri Dec 15 15:24:09 GMT 2023
Record UNII
O27Z9CH39A
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MORPHINE-3-GLUCURONIDE
Common Name English
MORPHINE 3-O-.BETA.-D-GLUCURONIDE
Common Name English
.BETA.-D-GLUCOPYRANOSIDURONIC ACID
Common Name English
.BETA.-D-GLUCOPYRANOSIDURONIC ACID, (5.ALPHA.,6.ALPHA.)-7,8-DIDEHYDRO-4,5-EPOXY-6-HYDROXY-17-METHYLMORPHINAN-3-YL
Systematic Name English
GLUCOPYRANOSIDURONIC ACID, MORPHINE-3, .BETA.-D-
Common Name English
Code System Code Type Description
WIKIPEDIA
MORPHINE-3-GLUCURONIDE
Created by admin on Fri Dec 15 15:24:09 GMT 2023 , Edited by admin on Fri Dec 15 15:24:09 GMT 2023
PRIMARY
EPA CompTox
DTXSID80174157
Created by admin on Fri Dec 15 15:24:09 GMT 2023 , Edited by admin on Fri Dec 15 15:24:09 GMT 2023
PRIMARY
FDA UNII
O27Z9CH39A
Created by admin on Fri Dec 15 15:24:09 GMT 2023 , Edited by admin on Fri Dec 15 15:24:09 GMT 2023
PRIMARY
CAS
20290-09-9
Created by admin on Fri Dec 15 15:24:09 GMT 2023 , Edited by admin on Fri Dec 15 15:24:09 GMT 2023
PRIMARY
PUBCHEM
5484731
Created by admin on Fri Dec 15 15:24:09 GMT 2023 , Edited by admin on Fri Dec 15 15:24:09 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> METABOLITE
PARENT -> METABOLITE INACTIVE
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)